Comprehensive analysis to identify transcriptomic signatures that positively or negatively correlate with clinical outcome of nivolumab monotherapy in patients with non-small cell lung carcinoma
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000027092
- Lead Sponsor
- Sendai Kosei Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Subjects with a condition requiring systemic treatment with either systemic corticosteroids or other immunosuppressive medications within 14 days of first nivolumab administration.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of transcriptomic signatures that positively or negatively correlate with clinical outcome of nivolumab monotherapy
- Secondary Outcome Measures
Name Time Method